Background Emerging evidence has linked the long-term use of bisphosphonates with femoral insufficiency fractures. It has been suggested that the prolonged effect on bone remodeling leads to the accumulation of microfractures and weakening of bone.
Introduction
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improves bone mineral density, prevents bone loss, and reduces the number of fractures in the spine and long bones [8, 9, 11, 15, 19, 38, 40, 43, 47, 50-52, 63, 66] . Although the short-term efficacy of bisphosphonates is well documented [7, 10, 28, 45, 64] , there are concerns regarding the safety of long-term therapy resulting from the effect on bone physiology [33, 35, 46, 49] . Bisphosphonates inhibit osteoclastic bone resorption, and therefore bone turnover, by inducing osteoclast apoptosis [39] . However, osteoclast function is vital for bone health through its link to osteoblast function. The combined and coordinated action of resorbing damaged bone and laying down new bone is fundamental to the process of bone remodeling. If this coupling is impaired, the microdamage that occurs under physiologic conditions that normally is repaired may accumulate, resulting in a major reduction in the energy required to cause fracture [4, 5, 31, 42, 59] .
The notion that bisphosphonates may have detrimental effects on bone physiology is not new. Data from animal models suggest alendronate suppresses bone turnover, causes a sevenfold increase in microdamage, and results in a 40% reduction in the energy required to cause fracture [4, 5, 27, 31, 37, 41, 42] . In addition, chronic oversuppression of bone turnover by bisphosphonates may allow secondary mineralization to continue, producing hypermineralized bone that may be more brittle [2, 13, 18, 46, 59] . Other theories to explain this association have been proposed, including those relating bone brittleness caused by long-term alendronate therapy to trabecular bone collagen cross-linking and isomerization [3, 55] . Others suggest it may be attributable to osteoclastic abnormalities or a variant form of osteoporosis [6, 65] . These effects last well beyond cessation owing to poor degradation of the drug, accumulation with use, and subsequent deposition in bone [10, 13, 14, 17, 20, 25, 32, 41, 46, 49, 53, 54, 59, 61, 65, 67] .
There is emerging evidence that the accumulation of microdamage from prolonged bisphosphonate therapy may be associated with femoral insufficiency fractures [1, 16, 23, 26, 30, 33, 35, 36, 44-46, 48, 49, 57, 58, 68] . These fractures are low-energy injuries and have characteristic findings observed on femoral radiographs: a transverse fracture line originating from the lateral tension side of the cortex and lateral cortical thickening adjacent to the fracture. In addition, prodromal thigh pain from the insufficiency changes may be present. The subsequent minimal trauma that often is required to complete the fracture is characteristic, with patients often sustaining a spontaneous nontraumatic fracture during activities of daily living. Despite the current evidence supporting an association between bisphosphonates and femoral insufficiency fractures, none of the studies determined the incidence of these fractures before introduction of alendronate, nor the incidence of alendronate use among patients with low-energy femoral fractures [1, 16, 23, 26, 30, 33, 35, 36, 44-46, 48, 49, 58, 68] .
We therefore asked the following questions: (1) Is there an association between bisphosphonate use and femoral insufficiency fractures? (2) Are these insufficiency fractures associated with long-term bisphosphonate use? (3) Did characteristic insufficiency fractures occur before the availability of bisphosphonates? (4) Are insufficiency fractures overrepresented by bisphosphonate users in patients presenting with low-energy femoral fractures? (5) What proportion of patients experience prodromal pain from insufficiency fractures? (6) What proportion of patients experience bilateral insufficiency fractures?
Patients and Methods
We retrospectively identified 100 patients who presented with low-energy subtrochanteric or midshaft femoral fractures from January 1995 to February 1997 and January 2007 to February 2009. These two periods coincided with the period before and after bisphosphonates became available for use. Low energy was defined as a fall from a standing height or less. We excluded patients younger than 65 years, or who had high-energy trauma, known underlying malignancy, or periprosthetic fractures. Thirty-eight patients were identified during the former period and 79 from the latter. Of the 38 patients identified from the former period, 17 (45%) did not have radiographs available for review. These patients were not included in the final analyses. Of 79 patients from the latter period, 41 (52%) were identified as having the characteristic insufficiency fracture pattern observed on plain radiographs. All but one of these 41 patients had been receiving prolonged alendronate therapy; the other had been taking risedronate. Fifty-three of the 79 patients from the latter period had a history of bisphosphonate use. The mean ages were similar between the two groups. The mean American Society of Anesthesiologists (ASA) scores also were similar between groups, suggesting both groups had comparable comorbidities. Demographics (Table 1 ) and clinical characteristics (Table 2 ) for all patients with low-energy femoral fractures are presented.
The medical records, patients, treating physicians, and family members were consulted to gather information regarding whether bisphosphonates were used, duration of use, presence of prodromal pain, mechanism of injury, and coexisting medical conditions. During the period after bisphosphonates became available (January 2007 to February 2009), 52 patients (66%) had a history of alendronate use. Of these patients, 48 had a history of alendronate use and four had a history of risedronate use. Radiographs were examined to identify the presence of preexisting insufficiency fractures. The characteristic findings observed on radiographs were a transverse fracture line on the lateral (tension) side of the femur and lateral cortical thickening adjacent to the fracture site (Fig. 1) . The radiographic outcome assessor was blinded regarding whether the patient was receiving bisphosphonate therapy.
We then identified the proportion of patients who were taking alendronate from all patients who presented with a proximal femoral fracture after a low-energy injury between January 2007 and February 2009. This allowed us to determine whether femoral insufficiency fractures were overrepresented by alendronate users compared with other fractures in a similar cohort of patients with similar mechanisms of injury.
We compared continuous variables using Student's t test. Categorical variables were analyzed using chi square or Fisher's exact test. Data were analyzed using Stata 8 statistical software package (College Station, TX, USA). Approval was given by the Human Research Ethics Committee.
Results
For patients presenting with low-energy femoral shaft fractures, bisphosphonate use was associated with the presence of an insufficiency fracture (Table 3) : the odds ratio of an insufficiency fracture in patients taking bisphosphonates was greater than 1000. All 41 patients who were identified as having insufficiency fractures were receiving or had received bisphosphonate therapy. Femoral insufficiency fractures were associated with long-term bisphosphonate therapy (Table 2) . Patients who had sustained insufficiency fractures after receiving bisphosphonate therapy had been taking the medication for an average of 7.1 years (95% confidence interval [CI], 6.6-7.6 years). The mean duration of bisphosphonate use in the 12 patients without insufficiency fractures was 3.2 years (95% CI, 2.6-3.8 years). The duration of bisphosphonate use was greater (p \ 0.001) in patients with an insufficiency fracture: 7.1 versus 3.2 years, respectively. Seven of 41 (17%) patients with insufficiency fractures were not currently taking a bisphosphonate but had stopped taking the drug between 6 months and 2 years prior. These patients received the drug for an average of 7.2 years.
There were no femoral insufficiency fractures identified in the 21 patients we examined during the period before bisphosphonates became available (January 1995 to February 1997).
For patients presenting with low-energy proximal and diaphyseal femoral fractures, bisphosphonate use was overrepresented among those with insufficiency fractures. Three hundred ninety-eight patients presented with lowenergy proximal femoral fractures between 2007 and 2009. Of these, only 52 (13%) were taking a bisphosphonate. For the same time period, the proportion of patients taking a bisphosphonate was greater in those presenting with femoral insufficiency fractures (98% versus 13%; p \ 0.001). The proportion of patients taking a bisphosphonate in the insufficiency fracture group also was greater (p \ 0.001) than the proportion of patients with subtrochanteric or femoral shaft fractures alone (98% versus 32%).
Twenty-nine (71%) of 41 patients with insufficiency fractures reported prodromal pain in the affected femur. The pain was localized to the groin, anterior thigh, lateral thigh, or knee and had been present for between 3 weeks and 6 months. Of these patients, 20 (69%) had experienced enough pain to warrant visiting their general practitioner or specialist physician at least once, and six (21%) subsequently were referred for radiographs. After obtaining radiographs, we identified femoral insufficiency fractures in all of these patients (Fig. 2) .
Eighteen (44%) of 41 patients with insufficiency fractures had bilateral femoral insufficiency fractures. Five (28%) of these patients previously had sustained a contralateral subtrochanteric fracture secondary to an underlying insufficiency fracture. Nine patients (22%) sustained spontaneous nontraumatic fractures during activities of daily living; eight of these (89%) patients were observed to have bilateral femoral insufficiency fractures (Figs. 2-4 ).
Discussion
Bisphosphonates are considered the first-line therapy for postmenopausal osteoporosis. However, many clinicians do not recommend bisphosphonate use beyond 5 years [8, 10, 21, 24] . This is predominantly the result of the unknown long-tem side effects and the fact that there rarely is any added benefit beyond this time [10] . Despite the widely accepted safety profile and tolerability of bisphosphonates, there has been concern regarding the safety of long-term therapy [33, 35, 46, 49] . It is purported that the bisphosphonate-induced prolonged impairment of bone remodeling leads to the accumulation of microfractures and weakening of bone [ Odds ratio = greater than 1000, p \ 0.0001; sensitivity = 100%, specificity = 80%, positive predictive value = 77%, negative predictive value = 100%. Fig. 2 A 68-year-old woman who had received long-term alendronate therapy presented to her physician with prodromal pain in the right anterolateral thigh. This radiograph was diagnostic for an insufficiency fracture (white arrow). This was missed by the referring physician and radiologist and the woman presented to us with a lowenergy subtrochanteric fracture at the site indicated by the arrow.
bisphosphonate therapy was by Odvina and colleagues in 2005 [46] . They discussed nine patients who had sustained spontaneous nontraumatic fractures while receiving alendronate therapy longer than 3 years. Their patients had delayed healing and histomorphometric evidence of severely suppressed bone turnover. The bone surface was devoid of cellular elements, the bone formation rate was reduced, and matrix formation was severely impaired. The authors concluded severe suppression of bone turnover might be a complication from long-term bisphosphonate therapy. Since the initial observations by Odvina et al., there have been numerous published reports of low-energy femoral insufficiency fractures in patients receiving longterm bisphosphonate therapy [1, 16, 23, 26, 30, 33, 35, 36, 44, 45, 48, 57, 58, 68] . All describe the characteristic fracture pattern and all attribute the radiographic findings to severe suppression of bone turnover from bisphosphonates. However, the rarity of these fractures is evidenced by the fact that the largest series published before now had 19 patients [45] . We performed the current study to further investigate the association between bisphosphonates and femoral insufficiency fractures (Table 4) , to examine whether these types of fractures were more common after the availability of bisphosphonates, and also to determine whether they were more common in patients taking bisphosphonates. Our study is limited by numerous factors. First, we may not have identified all cases of low-energy fractures, as the medical records could have incompletely, inaccurately, or ambiguously recorded the mechanism of injury. However, we suspect these would be a relatively small number as we examined the records of all patients with subtrochanteric and midshaft femoral fractures. Second, we may have underestimated the incidence of insufficiency fractures during the period before 1997 (before bisphosphonates were in mainstream use) because many of the radiographs were unavailable for review. Third, we defined an insufficiency fracture as one with a transverse fracture line on the Fig. 3A-B A 71-year-old woman presented with (A) a spontaneous nontraumatic left femoral shaft fracture while standing and was incidentally found to have (B) a femoral shaft insufficiency fracture on the right. The woman reported a 6-month history of prodromal left anterolateral thigh pain, a 2-month history of right anterior thigh pain, and a 10-year history of alendronate use. The bilateral femoral insufficiency fracture pattern can be seen (white arrows). lateral (tension) side of the femur and lateral cortical thickening adjacent to the fracture site. We believe this is an appropriate definition, but realize others might suggest a different definition.
Our data suggest a strong association between femoral insufficiency fractures and bisphosphonate therapy. These findings confirm those of other studies [1, 16, 23, 26, 30, 33, 35, 36, 44-46, 48, 57, 58, 68] . Although this does not establish cause and effect, it emphasizes the need for additional research into the causality and pathophysiology of these fractures. For example, identifying which people are more susceptible to insufficiency fractures would improve the safety and efficacy of bisphosphonates.
Our data also show that insufficiency fractures are associated with long-term bisphosphonate use, rather than bisphosphonate use per se. This supports the argument that longer-term bisphosphonate use results in prolonged impairment of bone remodeling, accumulation of microfractures, and weakening of bone [2, 4, 5, 10, 12-14, 17, 18, 20, 25, 27, 31, 32, 37, 41, 42, 46, 49, 53, 54, 59, 61, 62, 65, 67] . Again, more research is needed before definitive conclusions can be made.
We identified no patients with femoral insufficiency fractures during the period before bisphosphonates becoming available. This suggests that these fractures may have appeared only since the introduction of bisphosphonates, possibly being a direct result of them. However, as noted, we may have overlooked the presence of insufficiency fractures in this earlier period, because many of the radiographs were unavailable for review.
It could be argued that patients presenting with femoral insufficiency fractures originally were taking bisphosphonates because they were at greater risk of having osteoporotic fractures. However, one would expect the proportions of postmenopausal women taking bisphosphonates would have similar rates of femoral neck, intertrochanteric, and subtrochanteric fracture presentations, because all occur in similar populations through similar mechanisms of injury. In our study, however, 100% of patients who presented with femoral insufficiency fractures were taking bisphosphonates compared with only 13% of all other patients who sustained low-energy proximal femoral fractures. Similar findings have been reported elsewhere [27, 52] and highlight the overrepresentation of bisphosphonate use among those with femoral insufficiency fractures.
The high proportion of bilateral insufficiency fractures in our study has been observed by other authors [16, 26, 33, 35, 56, 57, 68] and provides more support for the argument that these changes have a systemic cause such as the oversuppression of bone turnover. Some authors have commented that suppression of bone turnover is more marked in patients receiving concurrent glucocorticoid and estrogen therapy and this may be why bilateral changes are seen in some people [46, 58] . However, we were not able to ascertain this from our study.
We do not interpret these findings to suggest alendronate is dangerous. Bisphosphonates are cost-effective treatment for management of osteoporosis and they reduce morbidity, disability, and mortality associated with fractures [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, our observations suggest care must be taken when prescribing bisphosphonates for prolonged periods and doctors should be alerted by symptoms of thigh pain in patients taking them, because this may be a symptom of insufficiency changes in the femoral shaft. It is unclear if early detection reduces the risk of fracture progression. However, cortical thickenings have a higher risk of progressing to complete stress fractures [30] . The management of bisphosphonate-induced femoral insufficiency fractures has yet to be well-established. Until we have evidence-based recommendations, it would be reasonable to cease prescribing bisphosphonate, but continue calcium and vitamin D supplementation and follow up with dual energy xray absorptiometry and bone resorption marker measurements. Furthermore, treatment with teriparatide (recombinant human parathyroid hormone) may be beneficial by reducing the accumulation of microdamage in patients previously treated with bisphosphonates [22, 29, 60] .
The unique subtrochanteric insufficiency fracture pattern that we have observed almost exclusively in bisphosphonate users is likely to represent a new type of pathologic fracture. As a result of the numbers of these patients who sustain spontaneous nontraumatic fractures during activities of daily living, it is the practice at our institution to prophylactically internally fix the fractures as soon as they are identified. Because the effects of bisphosphonates last well beyond their cessation date, we do not believe stopping the drug alone will be sufficient to prevent the progression to complete fracture.
Long-term bisphosphonate use is associated with insufficiency fractures of the femoral shaft, which commonly present with prodromal thigh pain and may be bilateral. Consideration should be given to stopping bisphosphonates after 5 years of continuous use. At the very least, patients taking bisphosphonates should be radiographically monitored and routinely questioned regarding prodromal pain.
